Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people
about
The effect of statins on average survival in randomised trials, an analysis of end point postponementSocial factors and cardiovascular morbidityTime trends in the prescription of statins for the primary prevention of cardiovascular disease in the United Kingdom: a cohort study using The Health Improvement Network primary care dataAmerican Diabetes Association indications for statins in diabetes: is there evidence?The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.A cardiovascular disease policy model that predicts life expectancy taking into account socioeconomic deprivation.Cost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian public health system.Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular riskCan cardiovascular disease guidelines that advise treatment decisions based on absolute risk be improved?Need for a paradigm shift in cancer prevention and clinical oncology.Clinical and economic benefits associated with the achievement of both HbA1c and LDL cholesterol goals in veterans with type 2 diabetes.Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial.From 4S to IDEAL: the health economics of the statin trials.An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial.Targets for body fat, blood pressure, lipids, and glucose-lowering interventions in healthy older people.Cost-effectiveness of statins revisited: lessons learned about the value of innovation.Does the benefit from statin therapy extend beyond 5 years?Recommendations to prescribe in complex older adults: results of the CRIteria to assess appropriate Medication use among Elderly complex patients (CRIME) project.Challenges in modelling the cost effectiveness of various interventions for cardiovascular disease.A systematic literature review of methods of incorporating mortality in cost-effectiveness analyses of lipid-lowering therapies.You Only Die Once: Accounting for Multi-Attributable Mortality Risks in Multi-Disease Models for Health-Economic Analyses.Economic evaluation of factorial randomised controlled trials: challenges, methods and recommendations.The lesser known effects of statins: benefits on infectious outcomes may be explained by "healthy user" effect.The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.How do prescribing doctors anticipate the effect of statins?Statins utilisation pattern: a retrospective evaluation in a tertiary care hospital in Thailand.Using statins to treat 'healthy' patients: are we there yet?Quality of life and time to death: have the health gains of preventive interventions been underestimated?Decision Making for Healthcare Resource Allocation: Joint v. Separate Decisions on Interacting Interventions.
P2860
Q26786733-9C7FF12C-E318-4468-A28A-8CB4615C2CB4Q28393882-CEC995C7-A75D-4B63-B3E1-09C2D90118ACQ31108693-BBD3A7E6-0B6E-4079-B1F1-24AD1F6ECFB8Q33610712-83D67F7C-D3E7-4E14-886A-F2587CB23DA0Q34274829-E755BC15-26DA-43E6-AF84-3738498AD5F5Q35048588-510AA053-34ED-45D8-AA40-713C037C89FBQ35292482-52B342A6-11C3-406F-943A-014A470E18DFQ35551084-4EB27FEA-0E6F-40BD-801B-0C4C80B61288Q36193205-E221B904-F545-40E6-8781-B052E7141687Q36974680-FB381ED4-1D53-4426-839F-2F5ED719AE90Q37193496-2C829127-671E-48C7-9D13-3FA9F9565A41Q37419427-19E062A4-D236-498A-A1CB-C4394B3E6DDDQ37451199-1356EF01-C5E7-4496-B2E1-84E5B09D7445Q37484543-43EC91B0-78CF-4234-B1C9-30B29D043165Q37577151-997C3F00-AB6C-4C73-818C-9D886285A126Q37870094-81E387E3-D9A0-469C-8BE2-1DBC531DAA00Q38072611-1B750415-C13F-4359-9142-F00C5921FD72Q38162813-0FC355BB-7445-44F2-AC15-B031A207A719Q38205728-CEB6D0A3-CDEC-439D-9D18-CE4E0AAC733DQ38754290-037909A7-AA7E-4287-B08E-77AF0AA1C10FQ39609247-938761A9-2CC8-4CEF-9150-42B0E4211F75Q41990253-B97BCB5C-2830-4520-84F3-9BAF15614FBCQ43204745-086EC906-7B76-4600-8A06-A51F4757084FQ44047476-D494E524-54CE-4B7F-85CC-EE77BB51CE89Q44226345-5C8C1C04-1CB3-4B59-94F5-2656038F05AEQ45210049-6FBFD40C-266F-458A-9F22-F90F0F0C2499Q46032039-89F74D27-8731-4A89-A6A9-6E2EEF9EC2ADQ48061868-82C6F84B-F0B2-4C4B-BD1B-55F3AA085A49Q54943893-E8C3CA73-0599-444E-8D9E-527473C51454
P2860
Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Lifetime cost effectiveness of ...... domised trial of 20,536 people
@ast
Lifetime cost effectiveness of ...... domised trial of 20,536 people
@en
type
label
Lifetime cost effectiveness of ...... domised trial of 20,536 people
@ast
Lifetime cost effectiveness of ...... domised trial of 20,536 people
@en
prefLabel
Lifetime cost effectiveness of ...... domised trial of 20,536 people
@ast
Lifetime cost effectiveness of ...... domised trial of 20,536 people
@en
P2093
P2860
P1433
P1476
Lifetime cost effectiveness of ...... domised trial of 20,536 people
@en
P2093
Alastair Gray
Andrew Briggs
Heart Protection Study Collaborative
Jane Armitage
Rory Collins
P2860
P356
10.1136/BMJ.38993.731725.BE
P407
P577
2006-11-10T00:00:00Z